Kyverna Therapeutics, Inc. (KYTX) financial statements and ratios from SEC XBRL: revenue $9.09M (TTM), net margin -1773.8%, revenue growth -40.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $9.09M |
| Net Margin | -1773.8% |
| Revenue Growth (YoY) | -40.8% |
| EPS Growth (YoY) | 9.3% |
| FCF Growth (YoY) | 32.0% |
| Price / Book | 3.14 |
| Price / Sales | 60.52 |
| FCF Yield | -39.0% |
| Altman Z-Score | 2.06 (grey) |
| Sector P/E (Healthcare) | 21.7 |
KYTX overview · KYTX earnings · KYTX KPIs · KYTX investor relations · KYTX ownership · KYTX peers · KYTX filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.